TAT-10: Production of a Thorium/Actinium Generator at the Canadian Nuclear Laboratories

Kanazawa, Japan (UroToday.com) The Canadian Nuclear Laboratory (CNL) at Chalk River, Ontario has a stockpile of U233 which is used to construct a Thorium/Actinium generator for the production of Ac225. A Thorium fraction containing most the desired isotope Th229 has been isolated with anion exchange and chromatographic techniques.

Subsequently an Eichrom method was used to extract the Actinium. Purified Ac225 was isolated and labeled to an anti-epithereal growth factor (EFGR) antibody. Ac225-DOTA-nimotuzumab is an effective alpha therapy agent against EFGR+ cancers

As of now, the regular milking of the U-Th-Ac generator has yielded MBq quantities of Ac225. Improvements, including an automated system, are under way.

The resulting Ac225 was used to label DOTA- nimotuzumab with radiochemical yield of 25% and purity 95% and a specific activity of 0.03 MBq/microgram.

Presented By: Patrick Causy from Canadian Nuclear Laboratory, Chalk River, Canada

Written By: William Carithers, Lawrence Berkeley National Laboratory

at the 10th International Symposium on Targeted Alpha Therapy (TAT-10)  May 31 - June 1, 2017 - Kanazawa, Japan.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe